UC study examines role of metabolites in disease treatment
Findings could result in first-of-its-kind treatments for an aortic aneurysm
Each year, about 200,000 people in the United States are diagnosed with a bulge in the lower part of the aorta, the main artery in the body, called an abdominal aortic aneurysm (AAA).
New research from the University of Cincinnati examines the role a particular metabolite plays in the development of AAA and could lead to the first treatment of the condition.
The research was published in the journal Circulation.
“We started the study by examining whether AAA patients themselves had an increase in trimethylamine N-oxide (TMAO). We examined an American and Swedish cohort with 354 human samples, and we compared those AAA patients to 1,775 control subjects,” says Phillip Owens, PhD, co-first author of the study along with Tyler Benson, PhD, both of the Division of Cardiovascular Health and Disease in the UC College of Medicine. “We started going into animal models after that, looking at what happens when we feed a high choline diet which leads to higher production of TMAO.”
Choline, found in a variety of foods with the richest sources being meat, fish, poultry, dairy and eggs, is processed into the organic compound TMAO when meat is digested by the bacteria in the gut.
The research found that in humans, TMAO levels were increased in AAA patients, but that doesn’t mean it is causing the disease state, according to Owens. To see if TMAO had an actual effect, researchers tried to replicate it in an animal model to manipulate the levels of TMAO and then block those in the subject to see whether TMAO increases were exacerbating the disease.
“We found that a high choline diet produces increased levels of AAA, and increased aneurysm rupture as well,” says Owens. “When we take that same model and inhibit the levels of TMAO using gut microbial inhibitors, inhibiting the conversion of the choline to the trimethylamine to the TMAO, we were able to reduce the levels of choline-induced AAA. It was in fact not the choline, but the choline-induced TMAO that led to an increase in aneurysm.”
Owens says the research came about as the result of interest expressed in the topic by former UC College of Medicine student Kelsey Conrad, PhD, who is a co-first author on the paper.
“It’s always one of my goals to try to get a project that interests the student, not just have them do something in my lab that I need to get done,” says Owens. “We created this project for that student then we filed a grant and found the funds. It’s not usually the way it goes.”
Conrad says she’s grateful to have worked with a mentor in Owens who supported her growth in a way that considered her past experiences and aligned with her professional goals.
“The potential for this work to radically change clinical care and improve patient outcomes in AAA is very exciting,” says Conrad who is now a faculty member at Smith College in Massachusetts. “Selectively targeting the gut microbes to prevent the progression of disease for this population would be a novel therapy for these patients who currently lack any pharmacological treatment options.”
Where I’m excited is if these inhibitors do make it to market, it’s potentially something in our arsenal that we can have for AAA where right now we have nothing.
Phillip Owens, PhD
There are an estimated 1 million men and women with AAAs in the United States and Owens says when you extrapolate that to the world population of 7 billion, that means potentially 20 to 30 million people worldwide have an AAA.
“We’ve gotten it to work in animal models which doesn’t necessarily mean it’s going to work in humans,” says Owens. “I think if the data has shown us one thing, it’s that TMAO is markedly increased in several cardiovascular diseases and if you inhibit it, at least in animal models, you do impact inflammation and overall mortality. Where I’m excited is if these inhibitors do make it to market, it’s potentially something in our arsenal that we can have for AAA where right now we have nothing.”
That may be a possibility sooner than later, Owens adds. Stanley Hazen at the Cleveland Clinic and co-author on the study, developed the drug fluoromethyl choline used in the studies and is constantly working on refining these inhibitors, which are currently being evaluated for their efficacy to inhibit TMAO in humans.
Lead photo at top of Phillip Owens/Andrew Higley/UC Marketing + Brand
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Cincinnati researchers want to know if MRIs can work better
June 28, 2024
WVXU and the Cincinnati Business Courier highlighted a new collaboration between the University of Cincinnati College of Medicine, UC Health GE HealthCare, JobsOhio, REDI Cincinnati and Cincinnati Children’s to create an MRI Research and Development Center of Excellence located on UC’s medical campus.
UC opens Blood Cancer Healing Center
June 28, 2024
Media outlets including WLWT, Local 12, Spectrum News, the Cincinnati Enquirer and Cleveland.com highlighted the opening of the University of Cincinnati Cancer Center's Blood Cancer Healing Center.
New project aims to better support teen mothers in Adams County
June 27, 2024
WCPO highlighted a partnership between the University of Cincinnati and the Adams County Health Department that is aiming to provide better support for teen mothers in the county.
Free Wi-Fi, work area coming to Greater Cincinnati
June 27, 2024
St. Lawrence Park in Price Hill now has free Wi-Fi and a furnished outdoor space for community members to access digital needs. The space is part of The Nodes Project, which stands for “Neighborhoods of Design Engagement": a collaboration between UC DAAP communication designers and community entities.
Study aimed at reducing opioid overdose deaths presents results
June 27, 2024
The University of Cincinnati's John Winhusen and Caroline Freiermuth discussed the evidence-based practices implemented during the HEALing Communities Study to fight the opioid epidemic with Spectrum News.
University of Cincinnati, UC Health collaborate with GE HealthCare on MRI research center
June 26, 2024
The University of Cincinnati and UC Health are collaborating with GE HealthCare, JobsOhio, REDI Cincinnati and Cincinnati Children’s to create an MRI Research and Development Center of Excellence located on UC’s medical campus.
The health impact of living near a natural gas leak
June 25, 2024
UC College of Arts and Sciences Professor Amy Townsend-Small talks to the BBC about the health issues faced by neighbors of leaking natural gas wells.
Male birth control gel inches towards FDA approval
June 25, 2024
The University of Cincinnati's Wesley Baas spoke with Yahoo News and the Cincinnati Enquirer about a new male birth control gel that could be close to receiving FDA approval.
University of Cincinnati Cancer Center launches Blood Cancer Healing Center
June 25, 2024
The University of Cincinnati Cancer Center celebrated the opening of its state-of-the-art Blood Cancer Healing Center June 24.
Emergency rooms see uptick with heat-related illnesses
June 24, 2024
The University of Cincinnati's Caroline Freiermuth spoke with Spectrum News about how to look for signs of heat-related illness.